Blocking integrin inactivation as an anti-angiogenic therapy.

During angiogenesis, endothelial cell migration is coordinated by integrinmediated contact with the extra-cellular matrix (ECM), coupled with receptor tyrosine kinase signalling to regulate dynamic cytoskeletal and plasma membrane reorganization. A recent paper by Vitorino et al (2015) defined a new MAP4K4– moesin–talin–b1-integrin pathway that could be therapeutically exploited to suppress pathologic angiogenesis.